These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34940894)

  • 1. Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment.
    Strobel SB; Machiraju D; Kälber KA; Hassel JC
    Cancer Immunol Immunother; 2022 Aug; 71(8):2051-2056. PubMed ID: 34940894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors.
    Gilbert D; Hu J; Medina T; Kessler ER; Lam ET
    Hum Vaccin Immunother; 2023 Dec; 19(1):2207438. PubMed ID: 37157982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study.
    Mei Q; Hu G; Yang Y; Liu B; Yin J; Li M; Huang Q; Tang X; Böhner A; Bryant A; Kurts C; Yuan X; Li J
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-Related Adverse Events Among COVID-19-Vaccinated Patients With Cancer Receiving Immune Checkpoint Blockade.
    Widman AJ; Cohen B; Park V; McClure T; Wolchok J; Kamboj M
    J Natl Compr Canc Netw; 2022 Oct; 20(10):1134-1138. PubMed ID: 36240845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serological response and immune-related adverse events following COVID-19 vaccination in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Wang Y; Chen D; Pan Y; Li H; Zhao W; Lu T; Kong W; Ding M; Wang X; Zhang G
    Rev Med Virol; 2024 Jan; 34(1):e2495. PubMed ID: 38017632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
    Ruiz JI; Lopez-Olivo MA; Geng Y; Suarez-Almazor ME
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36746512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in China.
    Zhang S; Li J; Xu R; Chen Q; Sun G; Lin Y; Cao Y; Chen Y; Geng C; Teng Y; Nie J; Li X; Xu G; Liu X; Jin F; Fan Z; Luo T; Liu H; Wang FS; Jiang Z
    JMIR Public Health Surveill; 2023 Dec; 9():e46009. PubMed ID: 38060302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
    Luo B; Li J; Hou X; Yang Q; Zhou Y; Ye J; Wu X; Feng Y; Hu T; Xu Z; He Y; Sun J
    Future Oncol; 2021 Sep; 17(26):3477-3484. PubMed ID: 34189948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review.
    Spagnolo F; Boutros A; Croce E; Cecchi F; Arecco L; Tanda E; Pronzato P; Lambertini M
    Eur J Clin Invest; 2021 Jul; 51(7):e13604. PubMed ID: 34021591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report.
    Lasagna A; Lenti MV; Cassaniti I; Sacchi P
    Immunotherapy; 2022 Aug; 14(12):915-925. PubMed ID: 35694999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
    Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events.
    Wijn DH; Groeneveld GH; Vollaard AM; Muller M; Wallinga J; Gelderblom H; Smit EF
    Eur J Cancer; 2018 Nov; 104():182-187. PubMed ID: 30368069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data.
    Grima AA; Kwong JC; Richard L; Reid J; Raphael J; Basta NE; Carignan A; Top KA; Brousseau N; Blanchette PS; Sundaram ME;
    Vaccine; 2024 Mar; 42(7):1498-1505. PubMed ID: 38341288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade.
    Niewolik J; Mikuteit M; Cossmann A; Vahldiek K; Gutzmer R; Müller F; Schröder D; Heinemann S; Behrens GMN; Dopfer-Jablonka A; Steffens S; Grimmelmann I
    Oncology; 2022; 100(7):392-398. PubMed ID: 35609553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysis.
    Ma Y; Liu N; Wang Y; Zeng J; Hu YY; Hao W; Shi H; Zhu P; Lv J; Fan W; Wang X
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34845005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
    Bhatlapenumarthi V; Patwari A; Harb AJ
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.